Molecular Pathology is an emerging discipline with a rapidly increasing demand and increasing repertoire of available tests. The Molecular Pathology team is dedicated to improving patient outcomes and its service to its users by investigating and implementing new technologies and tests as they become clinically relevant.
The team is currently working towards the development of:
- A panel of assays to support histological classification of renal cell carcinomas.
- Extended molecular testing for adult and paediatric CNS tumours.
-
Extended testing (RNA NGS for the detection of clinically relevant fusions and a small targeted DNA NGS panel) for patients with sarcomas.
-
TERT promoter testing for patients diagnosed with thyroid cancers.
-
A custom RNA NGS panel for the detection of common RNA fusions in a range of solid tumour samples (replacement of current FISH technology).